Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
about
Statins for primary prevention of venous thromboembolismStatins for the primary prevention of cardiovascular diseaseStatins for primary prevention of venous thromboembolismRosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspectiveThe effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trialsApoptotic cell clearance: basic biology and therapeutic potential.Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspectiveC-reactive protein, cardiovascular disease and stroke: new roles for an old biomarkerOngoing clinical trials of the pleiotropic effects of statinsCritical appraisal of C-reactive protein throughout the spectrum of cardiovascular diseaseValidation of biomarkers of CVD risk from dried blood spots in community-based research: methodologies and study-specific serum equivalenciesMicro-ultrasonographic imaging of atherosclerotic progression and correlation with inflammatory markers in apolipoprotein-E knockout miceEffectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data.The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.Implications of increased C-reactive protein for cardiovascular risk stratification in black and white men and women in the US.Eligibility for statin therapy by the JUPITER trial criteria and subsequent mortalityIntraindividual variability of C-reactive protein: the Multi-Ethnic Study of Atherosclerosis.Statins and cardiovascular diseases: from cholesterol lowering to pleiotropyElevated C-reactive protein levels and enhanced high frequency vasomotion in patients with ischemic heart disease during brachial flow-mediated dilation.Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authoritiesMy patient has an elevated hs-CRP. What does this mean? What should I do now?Pleiotropic effects of pitavastatinThe russert impact: a golden opportunity to promote primary coronary prevention.Evaluation of cardiovascular disease risk factors in patients with mycosis fungoides.Estimating treatment effects for individual patients based on the results of randomised clinical trials.Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia--Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating RosuvastatiRisk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease.Coronary heart disease risk reduction in postmenopausal women: the role of statin therapy and hormone replacement therapy.Anti-Inflammatory Dietary Combo in Overweight and Obese Women with Polycystic Ovary SyndromePharmacologic strategies for the prevention of atherosclerotic plaque progression.Statins: can the new generation make an impression?Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.C-reactive protein comes of age.Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.Anti-inflammatory effects of statins: clinical evidence and basic mechanisms.Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins.Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery
P2860
Q24187238-237D96A3-BEFF-4563-980D-41B59D221F83Q24201513-3898E1C9-684A-42D9-8BAE-797B7F06C974Q24204040-F4810214-53B4-4D81-90F7-99D2CD414935Q24594814-94F9E4E9-801D-45E0-A8CE-4DEFD1381F18Q24793837-25F0ABCB-3E4E-408F-8DC6-1604E7D33CABQ26776293-CEAB77A9-F5A8-491A-9016-667E1A7E4A20Q26825935-C47BCF46-8B79-4492-B2E4-7E8B1B50F156Q27002928-244A21DA-8983-45C1-A06B-AA2458A5CCBCQ28174368-7003962F-6626-469D-8EAC-9BED09FAD882Q28219321-E6E3A5D6-C0E0-44CA-87D2-80A8E6DA312EQ28219483-534AFF15-63DD-4509-A9EA-91F92056FCC7Q28390875-658C733F-8CBD-46A3-A837-F3590737D9B6Q30474537-E8BDA33C-072D-4BF4-A0B9-3E0056A84770Q31129888-88EB8869-217F-4476-8590-61B74E69ACC0Q33571213-66C8DC93-F7D6-424E-82A2-0A2EF2A335D7Q33605421-DB229194-93FC-40F8-8B51-CBCAC7909119Q33618846-72C16205-4803-47D9-999D-64A61DCAE1CBQ33857000-F795E35A-D150-406F-86CD-B6D8B38ACAE7Q33960556-9E840B7D-4980-471B-BE2C-ACD54EAC8703Q34316820-F0833E22-E6A2-47D2-A5AF-5AB34B1954D9Q34453538-8FF91691-23F9-4606-81AB-9159EF803A98Q34481383-407E7D65-EDC1-4C48-95B1-D15F056937A1Q34633506-452AB9DF-7EBE-4DAB-BF85-A8B733791006Q34986590-C650376C-51F9-4A82-936D-859494F294FBQ35070294-13DF1EA6-3CE7-4AB1-81A6-463D829CDEBDQ35252544-7273232B-8C3C-4CEF-8E9C-A60BE0509AF9Q35605494-59B0408A-3383-4CDC-862B-68B974730915Q35631575-7F996B53-E9E6-4EE7-A880-5F0F3A801E46Q35830997-94C18947-7BB8-4390-9FBF-289635C6BBA9Q35834128-2373947C-225C-43D7-8209-49B31C9E6243Q35917742-69E9DC56-584A-4A6F-8579-2DC6CD503C1FQ35925692-21B64CF7-BF45-4DEA-A66D-D5418DA55273Q35967383-389BFFFB-2E22-49BC-8DF4-87F1B65D3737Q36249934-287ADF7D-9D67-4C20-9708-76588941314AQ36268387-55ACC302-0F43-4BC1-9009-DC8F132E699CQ36304216-F34B0407-FE6E-4AF3-9E15-C59AB8D86A86Q36320560-CA7FC29F-3425-409E-993E-05C26FF85606Q36337932-F6C57864-F3B4-4963-B926-34590E8BC4DBQ36357787-ABA98EB4-07C1-4E34-A727-C3E2549E297FQ36369429-116A795A-86BB-4973-B621-49732422595B
P2860
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Rosuvastatin in the primary pr ...... d design of the JUPITER trial.
@ast
Rosuvastatin in the primary pr ...... d design of the JUPITER trial.
@en
Rosuvastatin in the primary pr ...... d design of the JUPITER trial.
@nl
type
label
Rosuvastatin in the primary pr ...... d design of the JUPITER trial.
@ast
Rosuvastatin in the primary pr ...... d design of the JUPITER trial.
@en
Rosuvastatin in the primary pr ...... d design of the JUPITER trial.
@nl
prefLabel
Rosuvastatin in the primary pr ...... d design of the JUPITER trial.
@ast
Rosuvastatin in the primary pr ...... d design of the JUPITER trial.
@en
Rosuvastatin in the primary pr ...... d design of the JUPITER trial.
@nl
P921
P1433
P1476
Rosuvastatin in the primary pr ...... d design of the JUPITER trial.
@en
P2093
JUPITER Study Group
Paul M Ridker
P304
P356
10.1161/01.CIR.0000100688.17280.E6
P407
P577
2003-11-01T00:00:00Z